Connect with us

Technology

ACCESS MEDICAL LABS CONFIRMS ELIZABETH HOLMES EXACT PFIZER STUDY RESULTS USING THE SAME COMPONENTS

Published

on

JUPITER, Fla., Feb. 28, 2025 /PRNewswire/ — In a stunning revelation that will reshape the conversation around Elizabeth Holmes and her work at Theranos, one of the largest Specialty Labs in the Nation has confirmed that Holmes’ diagnostic technology was in fact Accurate—and that her suppressed Test Result findings regarding Avastin®, a cancer drug were very accurate during the 15 month Pfizer study in 2007.

In 2007 and 2008, Holmes conducted a study for Pfizer investigating the angiogenesis process and the effect of Bevacizumab, an anti-VEGF antibody therapy used in cancer treatment under the brand name, Avastin® https://files.cand.uscourts.gov/files/18-CR-258%20USA%20v.%20Holmes/Trial%20Exh.%200143/Trial%20Exh.%200143%20Email.pdf

See page 0012 of Trial exhibit 0143. – bottom half of 0012 shows the Avastin® affect.

The Pfizer contract with Theranos was executed on December 12th 2006  worth $900,000.00. https://files.cand.uscourts.gov/files/18-CR-258%20USA%20v.%20Holmes/Trial%20Exh.%2014112/Trial%20Exh.%2014112%20Agreement.pdf

The study took place in clinics and in patient homes with her machine wirelessly transmitting Results to Theranos servers and the Pfizer portal during the course.

Her research demonstrated that while the drug initially appeared to suppress VEGF levels, that was only true using another companies reagent that is used by LabCorp and many labs across the nation called, R&D Systems VEGF ELISA. Avastin® is a monoclonal antibody that attaches to VEGF in the body to prevent the body from making blood vessels (angiogenesis) so the cancer will not spread. The problem is, ELISA testing using Antibodies, in fact the same antibody as Avastin, Anti-VEGF or better known as Bevacizumab. This causes a problem when testing for VEGF because you cannot detect it due to the same antibody being present. It doesn’t know VEGF is present, it is being blocked by Anti-VEGF.

She also discovered that Avastin causes what’s called a VEGF complex, which means the body starts creating TONS of VEGF. VEGF levels spiked dramatically—showing an alarming surge from an average of 140 pg/mL to over 8,000 pg/mL. This post-treatment VEGF REBOUND effect signals a rapid increase in blood vessel formation, which could exacerbate cancer proliferation rather than control it. Her study was also confirmed independently in 2023 by JAMA open network. https://www.cancertherapyadvisor.com/news/discontinuation-of-bevacizumab-in-ovarian-cancer-may-result-in-rebound/

Despite Holmes’ findings, Pfizer and Dr. Shane Weber who testified against Elizabeth Holmes in court, rejected the results on December 31st 2008. https://files.cand.uscourts.gov/files/18-CR-258%20USA%20v.%20Holmes/Trial%20Exh.%200167/Trial%20Exh.%200167%20Report.pdf

Holmes’ research was originally conducted using the Theranos Edison (TSPU – Theranos System Processing Unit), which ran proprietary assays to measure both free and total VEGF levels. Unlike traditional laboratory methods—which only detect unbound VEGF—the Theranos approach provided a complete picture, revealing the dangers of VEGF suppression therapy when treatment is discontinued.

Holmes’ Study was originally conducted using the Edison or aka the TSPU – Theranos Systems Processing Unit, which ran proprietary assays developed in house at Theranos and commercially available test kits used by Lab Giants, LabCorp and Quest. In this case of VEGF, she used her proprietary test measure both free and total VEGF levels. Unlike traditional laboratory methods—which only detect unbound VEGF—the Theranos approach provided a complete picture, revealing the dangers of VEGF suppression therapy when treatment is discontinued because she could detect the TOTAL VEGF.

Today, Access Medical Labs has demonstrated that:

Holmes’ technology was indeed Accurate.Conventional testing methods, such as those used by LabCorp may underreport the true impact of anti-VEGF drugs.When Bevacizumab exits the bloodstream, a VEGF rebound may occur and CANNOT be detected early enough due to VEGF being blocked which could drastically increase the spread of cancer.Our lab testing proves that Elizabeth Holmes did not lie. Her tests & machine worked.

Ryan ElHosseiny
Access Medical Labs
954-494-1664
www.accessmedlab.com

View original content:https://www.prnewswire.com/news-releases/access-medical-labs-confirms-elizabeth-holmes-exact-pfizer-study-results-using-the-same-components-302389018.html

SOURCE Access Medical Labs

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Bloomberg Introduces Spread-to-Benchmark Quoting for EUR and GBP Portfolio Trading Baskets

Published

on

By

LONDON, June 2, 2026 /PRNewswire/ — Bloomberg today announced the launch of Spread-to-Benchmark quoting and trading for Euro (EUR) and Sterling (GBP) denominated portfolio trades through its Portfolio Trading Basket Builder (PTBB). The new functionality expands the range of quoting protocols available for European credit portfolio trading and reflects growing client demand for spread-based execution workflows, alongside increased dealer support for the convention across EUR and GBP markets.

Spread-to-Benchmark quoting is a well-established protocol for USD credit portfolio trades and is used by market participants to evaluate and execute portfolio trades. By extending this workflow to EUR and GBP portfolio trades, Bloomberg enables clients and dealers to transact using a familiar spread-based methodology across additional credit markets. 

The introduction of Spread-to-Benchmark quoting for EUR and GBP baskets reflects increased client interest in evaluating portfolio trades through a spread-based lens and the growing adoption of spread-based execution workflows in European credit markets. The workflow provides market participants with an additional framework for assessing the relationship between credit spread risk and underlying government bond yields when pricing and executing portfolio trades. 

Additional Workflow Flexibility 
The workflow complements Bloomberg’s existing portfolio trading capabilities, which support the full range of market-standard quoting conventions, including Price, Yield, Spread-to-Benchmark and Spread based workflows that reference Bloomberg’s evaluated pricing service (BVAL). This gives clients flexibility to compare and execute portfolio trades using the quoting methodology that best aligns with their investment objectives, execution preferences and internal risk management processes. 

“European credit clients continue to look for execution workflows that reflect how they evaluate risk and monitor portfolio trading outcomes,” said Harry Street, Global Head of Credit and Equities Trading Product at Bloomberg. “By expanding dealer support for Spread-to-Benchmark quoting for EUR and GBP baskets, Bloomberg is broadening the range of workflow options available to clients trading European credit portfolios.” 

“Portfolio trading workflows in fixed income continue to become more sophisticated as institutional investors look for ways to evaluate execution quality in changing market conditions,” said Kevin McPartland, Head of Market Structure & Technology Research at Crisil Coalition Greenwich. “Spread-based quoting helps market participants more clearly distinguish between the impacts of credit spread and underlying rates movements when determining how best to execute a portfolio trade.” 

Bloomberg’s Electronic Markets solutions are used by leading financial institutions to trade efficiently in over 175 markets around the world. More than 9,000 client firms use Bloomberg Electronic Markets to access industry-leading depth and breadth of liquidity across asset classes from over 800 dealers globally. Bloomberg Electronic Markets provides market participants with comprehensive solutions across the trading lifecycle, including robust price transparency, analytics, automation and execution, powered by Bloomberg’s high-quality, multi-asset class data and tools.

About Bloomberg
Bloomberg is a global leader in business and financial information, delivering trusted data, news, and insights that bring transparency, efficiency, and fairness to markets. The company helps connect influential communities across the global financial ecosystem via reliable technology solutions that enable our customers to make more informed decisions and foster better collaboration. For more information, visit Bloomberg.com/company or request a demo.

View original content to download multimedia:https://www.prnewswire.com/news-releases/bloomberg-introduces-spread-to-benchmark-quoting-for-eur-and-gbp-portfolio-trading-baskets-302787922.html

SOURCE Bloomberg L.P.

Continue Reading

Technology

Dr. Sunho Kang, a senior battery-technology executive with leadership experience at major global battery and EV manufacturers, joins TeraWatt Technology as Head of Product and Technology

Published

on

By

SAN FRANCISCO, June 2, 2026 /PRNewswire/ — TeraWatt Technology Inc. (Headquartered in California, USA) is pleased to announce that Dr. Sunho Kang has joined the company as Head of Product and Technology.

Dr. Kang is a globally recognized battery-technology executive with more than 25 years of leadership experience spanning the United States, Asia, and Europe, and a distinguished track record of advancing innovations from laboratory research through gigafactory-scale production. He has held senior executive positions at world-leading organizations including Samsung SDI, Apple, and Volkswagen Group of America, and brings deep expertise in lithium-ion battery materials, cell engineering, and product industrialization across a broad range of applications, including electric vehicles and energy storage systems.

At TeraWatt, Dr. Kang will lead global product development and the commercialization of TeraWatt’s battery technology platform, aiming to accelerate the delivery of TeraWatt’s competitive products as well as the technology and commercialization roadmap including manufacturing scale-up.

Dr. Kang commented:

“I am thrilled to join TeraWatt Technology as Head of Product and Technology. TeraWatt’s innovative battery platform presents a tremendous opportunity to push the boundaries of lithium-ion technology, and I look forward to working with the team to accelerate product development and commercialization to deliver meaningful impact.”

TeraWatt Technology founder CEO Ken Ogata, Ph.D. commented:

“We are thrilled to welcome Dr. Kang as our Head of Product and Technology. His deep expertise in battery materials, cell engineering, and productization will be instrumental in accelerating TeraWatt’s product roadmap and technology leadership. Together with Dr. Kang, we will continue to drive our mission forward.”

About TeraWatt Technology Inc.
TeraWatt Technology Inc. is a California-based company that produces lightweight, high-power, and safe next-generation lithium-ion batteries.

Company Overview
Name: TeraWatt Technology Inc.
Representative: Co-founder and CEO Ken Ogata
Headquarters: 28 Geary St, Suite 650, San Francisco, CA 94108, United States
Founded: January 2020
Established: December 2019
URL: https://www.terawatt-technology.com/

 

View original content:https://www.prnewswire.com/news-releases/dr-sunho-kang-a-senior-battery-technology-executive-with-leadership-experience-at-major-global-battery-and-ev-manufacturers-joins-terawatt-technology-as-head-of-product-and-technology-302786854.html

SOURCE TeraWatt Technology Inc.

Continue Reading

Technology

Tencent Cloud and Soniox Announce Strategic Partnership: Combining Advanced Speech-to-Text (STT) Technology with Global Real-Time Infrastructure

Published

on

By

HONG KONG, June 2, 2026 /PRNewswire/ — Tencent Cloud, the cloud business of global technology company Tencent, today announced a strategic partnership with Soniox, a San Francisco-based speech AI company that specializes in developing high-accuracy, low-latency speech AI solutions. The collaboration integrates Soniox’s speech-to-text (STT) technology with Tencent Cloud’s Real-Time Communication (TRTC) enterprise-grade global infrastructure, enabling enterprises to build and deploy multilingual voice AI applications across 200+ countries and regions.

Elevating Enterprise Voice AI at a Global Scale

In enterprise voice AI deployments, latency directly affects user experience and application reliability. The integration of Soniox’s high-accuracy, low-latency STT with TRTC’s global transmission infrastructure reduces latency across the entire pipeline, creating a comprehensive end-to-end solution for enterprises deploying conversational AI applications worldwide.    

Soniox is the voice platform for every language. Unlike legacy speech AI, which was built primarily for English-speakers, Soniox delivers native-speaker accuracy across 60+ languages. Its technology can handle mid-sentence language switching — a user can switch between English and Chinese in a single utterance, and Soniox will capture every word with complete accuracy. All of this works through a single API that works for both speech-to-text and text-to-speech.

By integrating TRTC, the partnership leverages an enterprise-grade real-time communication backbone featuring more than 3,200 global nodes, sub-300 ms worldwide latency, and advanced capabilities such as AI noise suppression and weak-network resilience. These capabilities enable conversational AI applications to operate reliably across diverse network environments, including regions such as Southeast Asia and Africa.

With the roll out of this partnership, developers can integrate the Soniox STT API directly within the Tencent Cloud console. Whether targeting English-speaking markets or supporting languages such as Arabic, Hindi, and Malay, enterprises can build global voice applications — including intelligent customer service, voice assistants, real-time translation, and meeting transcription — to address the demands of expansion into emerging markets and multilingual scenarios.

Wison Xie, Head of Product at Tencent RTC, stated: “Tencent RTC has always been committed to providing reliable real-time communication infrastructure for global enterprises. Our partnership with Soniox brings together our strengths in enterprise-grade audio transmission and Soniox’s advanced speech recognition technology. Together, we are making it easier for businesses to deploy accurate, low-latency voice AI applications across any language and any market.”

Klemen Simonic, CEO at Soniox Inc., stated “At Soniox, our mission is to help businesses understand every word, in any language, with native speaker accuracy and exceptional speed. Partnering with Tencent Cloud combines our speech AI with world-class real-time infrastructure, enabling enterprises to build voice AI experiences that scale globally with low latency and reliability.”

About Tencent Cloud:

Tencent Cloud, one of the world’s leading cloud companies, is committed to creating innovative solutions to resolve real-world issues and enabling digital transformation for smart industries. Through our extensive global infrastructure, Tencent Cloud provides businesses across the globe with stable and secure industry-leading cloud products and services, leveraging technological advancements such as cloud computing, Big Data analytics, AI, IoT, and network security. It is our constant mission to meet the needs of industries across the board, including the fields of gaming, media and entertainment, finance, healthcare, property, retail, travel, and transportation.

About Tencent RTC:

Tencent RTC provides real-time communication solutions, including audio/video calling, live streaming, and in-game voice. With enterprise-grade security, AI-powered enhancements, and a global network of over 3,200 nodes, Tencent RTC powers mission-critical communication for customers worldwide.

About Soniox:

Soniox is a next-generation voice AI company bringing about the end of English-first speech AI. Most people on the planet did not grow up speaking English and often mix languages mid-sentence; and yet legacy speech AI was built for just English. Soniox is different: native-speaker accuracy across 60+ languages, true mid-sentence language switching, and flawless alphanumeric recognition that legacy providers still can’t match. For developers building global apps, Soniox is the only option. Try it for yourself at soniox.com.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/tencent-cloud-and-soniox-announce-strategic-partnership-combining-advanced-speech-to-text-stt-technology-with-global-real-time-infrastructure-302786832.html

SOURCE Tencent Cloud

Continue Reading

Trending